Corestem Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
3,655
12,988
18,571
17,953
18,094
Cost of Goods Sold (COGS) incl. D&A
2,820
9,712
12,833
13,117
15,025
Gross Income
834
3,276
5,739
4,836
3,070
SG&A Expense
3,203
4,987
4,276
6,432
8,061
EBIT
2,406
1,804
1,368
1,624
5,071
Unusual Expense
853
3,781
917
227
1,520
Non Operating Income/Expense
2
30
31
53
679
Interest Expense
833
974
15
-
86
Pretax Income
3,914
6,280
704
1,264
5,715
Income Tax
482
46
426
46
961
Consolidated Net Income
3,432
6,325
277
1,218
4,755
Net Income
3,575
6,802
512
1,664
4,007
Net Income After Extraordinaries
3,575
6,802
512
1,664
4,007
Net Income Available to Common
3,575
6,802
512
1,664
4,007
EPS (Basic)
227.00
432.00
36.00
106.00
255.00
Basic Shares Outstanding
16
16
14
16
16
EPS (Diluted)
227.27
432.39
35.88
105.87
254.91
Diluted Shares Outstanding
16
16
14
16
16
EBITDA
2,049
871
2,440
445
3,564
Other Operating Expense
36
93
95
28
79
Non-Operating Interest Income
181
309
299
185
283
Minority Interest Expense
143
476
789
446
748

About Corestem

View Profile
Address
2/F, I & C Building
Seongnam GY 13486
Korea, Republic Of
Employees -
Website http://www.corestem.com
Updated 09/14/2018
CORESTEM, Inc. engages in the development and distribution of gene therapy products. The company was founded on December 29, 2003 and is headquartered in Seoul, South Korea. .